We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 13, 2021

Erenumab for Preventing High-Frequency Migraine



Additional Info

Disclosure statements are available on the authors' profiles:

Erenumab in the Prevention of High-Frequency Episodic and Chronic Migraine: Erenumab in Real Life in Italy (EARLY), the First Italian Multicenter, Prospective Real-Life Study
Headache 2020 Dec 18;[EPub Ahead of Print], P Barbanti, C Aurilia, G Egeo, L Fofi, S Cevoli, B Colombo, M Filippi, F Frediani, F Bono, L Grazzi, A Salerno, B Mercuri, A Carnevale, C Altamura, F Vernieri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading